Cost-effectiveness of Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy using a French healthcare perspective.

ABSTRACT:

SUBMITTER: Cotte FE 

PROVIDER: S-EPMC12929265 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature